Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05878236 · ClinicalTrials.gov registry record

iMmune SignAtures and Clinical outComes in AP

A clinical trial of Acute Pancreatitis, sponsored by Ohio State University.

Recruiting
Registry status
198
Enrollment target
5
Study locations

NCT05878236: Recruiting study of Acute Pancreatitis, sponsored by Ohio State University.

NCT05878236 is a study of Acute Pancreatitis that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 198 participants, below the 2,299-participant average among 10 other Acute Pancreatitis trials with a reported enrollment target (91% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05878236, a study of Acute Pancreatitis, is actively recruiting participants, sponsored by Ohio State University.

RECRUITING
Registry status
198 participants
Enrollment target
5
Study locations

Study Summary

The MoSAIC study is a prospective, observational study designed to develop an early prediction tool for severe acute pancreatitis (SAP) and define a distinct immunologic profile compared to moderate acute pancreatitis (MAP). The aims are to validate a new multi-cytokine panel for early prediction of SAP and to identify the specific immune cells that correspond with cytokine signatures in early acute pancreatitis to characterize the immune pathways driving the development of SAP. Participants will provide blood samples and complete patient surveys and interviews within 36 hours of hospital presentation, at 48 hours, and hospital day 7 (if admitted). Data on hospital stay, medical history, clinical course, and severity of disease will be collected.

Primary Outcome

Validate a novel multi-cytokine panel for early prediction of severe acute pancreatitis. The panel includes IL-8, TNFa R1, HGF, Resistin and Angiopoietin-2.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST CyTOF Analysis

Study Locations (5)

California

  • University of Southern California - Los Angeles

Illinois

  • University of Illinois Chicago - Chicago

Ohio

  • The Ohio State University - Columbus

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Washington

  • Benaroya Research Institute - Seattle

Trial Details

FieldValue
Enrollment Target 198 participants
Start Date 2023-03-06
Est. Completion 2027-12-31
Ohio State University

552 total trials

What NCT05878236 shows while recruiting

NCT05878236 is an observational study that tracks outcomes without assigning an intervention. The registered 198 participants enrollment target is mid-sized for trials with a published cap, below the 2,299-participant average among 10 other Acute Pancreatitis trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Acute Pancreatitis appearing as the primary indexed condition, and to 1 intervention - of which CyTOF Analysis is the first listed.

NCT05878236 lists 5 locations in 5 states (California, Illinois, Ohio).

Frequently Asked Questions

What is clinical trial NCT05878236 about?

NCT05878236 is a clinical study titled "iMmune SignAtures and Clinical outComes in AP". The MoSAIC study is a prospective, observational study designed to develop an early prediction tool for severe acute pancreatitis (SAP) and define a distinct immunologic profile compared to moderate acute pancreatitis (MAP). The aims are to validate a new multi-cytokine panel for early prediction of...

What is the current status of trial NCT05878236?

This trial is currently recruiting. The enrollment target is 198 participants. The study started on 2023-03-06. Estimated completion is 2027-12-31.

What conditions does trial NCT05878236 study?

This clinical trial studies the following conditions: Acute Pancreatitis.

What interventions are being tested in trial NCT05878236?

The interventions under investigation include: CyTOF Analysis (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05878236?

This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05878236 being conducted?

This trial has 5 study locations across California, Illinois, Ohio, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Pancreatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05878236's enrollment target sits among peer trials

198 6th of 10 higher than 5 of 10 other Acute Pancreatitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Pancreatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05203328 · 198 participants · NA

    Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy

  • NCT05426967 · 198 participants · NA

    rTMS for Military TBI-related Depression

  • NCT05561114 · 198 participants · Phase 3

    Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus

  • NCT05585190 · 198 participants · NA

    Stand Up for Your Health with a Sit-stand Desk

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05878236, the US trial registry maintained by the National Library of Medicine. NCT05878236 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.